ElMindA

ElMindA was founded in 2006 to address an unmet need for objectively assessing brain health and brain-related disorders over the course of an individual’s lifetime. ElMindA translates state-of-the-art neuroscience via advanced algorithmic science into clinically meaningful Brain Network Activation (BNA™) maps. ElMindA’s BNA technology measures, analyzes and maps the complex activity underlying neurological function and dysfunction. BNA™ can provide clinicians with the information they need about an individual’s brain health and disorder to make well-informed critical decisions. ElMindA is led by a highly experienced team and is backed by a world-renowned scientific board, key opinion leaders and collaborators from leading institutions. The company has established a database of more than 7,000 BNA™ maps from both healthy subjects and patients with brain related disorders. The data provide a robust, clinically supported foundation to potentially help identify and manage neurological disorders such as ADHD or pain, and brain injuries such as concussion. Prominent clinical institutions around the globe are leading research studies focused on the use of BNA™ across several of these areas. ElMindA is a preferred partner of industry-leading organizations based on the rigor of its science and technology development.

BNA Maps Creations

 

In 2014, Brain Network Activation (BNA) gained regulatory clearance for marketing in the United States (FDA) and Europe (CE). BNA enables the visualization and quantification of discrete neural networks and the quantitative assessment of interconnectivity of these systems that are associated with brain function, dysfunction, disease progression, response to therapeutic interventions and recovery. These network patterns are evoked while the patient performs a task; his or her brain activity is recorded using a 64 electrode EEG cap that measures evoked brain waves (Evoked Response Potentials or ERPs). ERP is a direct measure of neuronal activity that occurs in preparation for, or in response to a visual, auditory or somatosensory stimulus. BNA applies advanced algorithmic analysis methods to the multichannel EEG-ERP data and provides a map of functional network activity, connectivity and quantitative scores.

This method takes the leap from regional ERPs to large scale networks and also addresses the traditional weaknesses of EEG/ERP by standardizing the data acquisition, separating between noise and signal, automating pre-processing, and developing other complex reference brain networks. BNA™ transforms cognitive electrophysiology into a powerful brain mapping, imaging, and monitoring tool that serves as a biomarker for functional brain changes induced by disease and/or therapeutic interventions.

The patient’s specific BNA patterns can be used as a Benchmark to assess and establish an individual’s healthy brain network activity. The results of a benchmark test can be compared to the results of BNA follow up tests. These results and the respective comparisons help physicians understand recovery patterns and make more informed clinical decisions.  For patients who do not have a personal Benchmark, BNA can quantify recovery by comparing the overall similarity of the individual’s network activity with the network activity of a healthy population database.

 

BNA in action clip – face recognition task

Over the last decade, leading research institutions in Europe, the US and Canada, have integrated BNA in studies across a spectrum of brain related indication such as ADHD, depression, stroke and pain management. Pharmaceutical companies have also adopted BNA as a monitoring tool in early phases of drug development for various indications including Parkinson disease, pain, migraine, addiction, depression and cognitive impairment. Using BNA™ at early development and clinical trials phases can provide the pharmaceutical companies with additional information on the drug effect and mechanism of action of the drug. Based on the growing need for better concussion management tools, multiple studies were performed to evaluate the clinical utility of BNA in concussion. As of 2014 leading concussion centers in the US have started to integrate BNA into their clinical protocols. These centers are offering pre-season BNA benchmark tests to clubs, teams, schools and other sport organizations. BNA has been added to the toolsets that these centers use for post injury management, providing clinicians with a direct and objective layer of information. BNA is not used as a diagnostic tool, however it is used to support return to play decisions, monitor long term effects caused by post-concussion syndrome and response to treatment.